Fraunhofer-Institut für Biomedizinische Technik (IBMT)
The strategy of the Fraunhofer Institute for Biomedical Engineering (IBMT) is focused on the areas of biomedical/medical engineering (especially non-invasive and minimally invasive as well as miniaturized technologies), biotechnology, implants, cryotechnology, biobanks and stem cell research. Decades of expertise in biotechnological and medical research and development fields also allows Fraunhofer IBMT to solve a variety of purely technical tasks including automated in vitro culture devices. For many years, Fraunhofer IBMT has been working successfully in the field of stem cell research and has been the first institute of the Fraunhofer-Gesellschaft to obtain licences of the Robert Koch Institute to import and use human embryonic stem cells for scientific purposes. In recent years this has been extended to the production and characterization / expansion of induced pluripotent stem cells (iPSCs).
More information: www.ibmt.fraunhofer.de »
In the initial EBiSC phase, Fraunhofer IBMT established the mirror bank, coordinated and developed automation strategies for iPSC expansion and cryopreservation, and adviced on innovative banking technologies. In EBiSC2, Fraunhofer IBMT is the project coordinator and contributes with its broad expertise to all work packages with the lead in automation / upscaling, project management and business development. Fraunhofer IBMT together with Charité will implement the required legal and administrative infrastructure for taking responsibility of the legal entity of the European iPSC biobank at the end of the funding period and will provide operational sustainability of the biobank beyond project duration in collaboration with DH-ECACC.